Skip to main content
SpringerLink
Log in

Comparison of fluorescence in situ hybridization and immunohistochemistry for assessment of HER-2 status in breast cancer patients

  • Published:
Journal of Huazhong University of Science and Technology [Medical Sciences] Aims and scope Submit manuscript

Summary

The accurate assessment of a proto-oncogene, human epidermal growth factor receptor-2 gene (HER-2), is extremely important for the therapy and prognosis of breast cancer. Currently, immunohistochemistry (IHC) is the method widely used for the detection of HER-2 protein. Fluorescence in situ hybridization (FISH) has been suggested to be a golden standard assay for HER-2 amplification. This study examined the expression and amplification of HER-2 in paraffin-embedded sections of breast cancer tissues, and compared the two methods on the measurement of HER-2 status. HER-2 gene and protein were determined in breast cancer samples from 52 Chinese women by FISH and IHC respectively. The findings indicated that the HER-2 gene amplification was found in 18 cases (34.6%) by FISH and the HER-2 protein over-expression (score 3+) in 15 cases (28.8%) by IHC. Immunohistochemically, 28.6% of the cases scored as 2+ and 93.3% of the cases scored as 3+ were HER-2-positive by FISH. There was a significant correlation between the HER-2 gene amplification and HER-2 protein over-expression in breast cancer (P<0.005). No correlation was noted between the HER-2 gene amplification and any of the clinicopathological parameters examined, including age, menopausal status, menarche age, tumor size, histological tumor type, histological grade, lymph node status, and the expression of ER and PR. It was concluded that the detection of HER-2 gene amplification in breast cancer by FISH is valuable and can compare with HER-2 protein detection by IHC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001,344(11):783–792

    Article  PubMed  CAS  Google Scholar 

  2. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med, 2007,131(1):18–43

    CAS  Google Scholar 

  3. Dolan M, Snover D. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice. Am J Clin Pathol, 2005, 123(5):766–770

    Article  PubMed  CAS  Google Scholar 

  4. Lal P, Salazar PA, Hudis CA, et al. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol, 2004,121(5):631–636

    Article  PubMed  Google Scholar 

  5. Kammori M, Kurabayashi R, Kashio M, et al. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer. Oncol Rep, 2008,19(3):651–656

    PubMed  Google Scholar 

  6. Merola R, Mottolese M, Orlandi G, et al. Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis. Eur J Cancer, 2006,42(10): 1501–1506

    Article  PubMed  CAS  Google Scholar 

  7. Kostopoulou E, Vageli D, Kaisaridou D, et al. Comparative evaluation of non-informative HER-2 immunoreactions (2+) in breast carcinomas with FISH, CISH and QRT-PCR. Breast, 2007,16(6):615–624

    Article  PubMed  Google Scholar 

  8. Kuo SJ, Wang BB, Chang CS, et al. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients. Taiwan J Obstet Gynecol, 2007,46(2): 146–151

    Article  PubMed  Google Scholar 

  9. Vincent-Salomon A, MacGrogan G, Couturier J, et al. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology, 2003,42(4):337–347

    Article  PubMed  CAS  Google Scholar 

  10. Hameed O, Chhieng DC, Adams AL. Does using a higher cutoff for the percentage of positive cells improve the specificity of HER-2 immunohistochemical analysis in breast carcinoma?. Am J Clin Pathol, 2007,128(5):825–829

    Article  PubMed  Google Scholar 

  11. Vanden Bempt I, Vanhentenrijk V, Drijkoningen M, et al. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas. Histopathology, 2005,46(4): 431–441

    Article  Google Scholar 

  12. Varshney D, Zhou YY, Geller AS, et al. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol, 2004,121(1):70–77

    Article  PubMed  CAS  Google Scholar 

  13. Itoh H, Miyajima Y, Umemura S, et al. Lower HER-2/chromosome enumeration probe 17 ratio in cytologic HER-2 fluorescence in situ hybridization for breast cancers. Cancer, 2008,114(2):134–140

    Article  PubMed  Google Scholar 

  14. Rasmussen BB, Andersson M, Christensen I, et al. Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002–2006. A nationwide study including correlation between HER-2 status and other prognostic variables. Acta Oncol, 2008, 47(4):784–788

    Article  PubMed  Google Scholar 

  15. Nam BH, Kim SY, Han HS, et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res, 2008,10(1):R20

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

    Lin Wang  (王 琳), Xiaobei Wang  (王晓蓓), Xiu Nie  (聂 秀) & Ling Ma  (马 玲)

Authors
  1. Lin Wang  (王 琳)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaobei Wang  (王晓蓓)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiu Nie  (聂 秀)
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ling Ma  (马 玲)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lin Wang  (王 琳).

Additional information

This project was supported by a grant from Ministry of Public Health of China (No. WKJ2007-3-001).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, L., Wang, X., Nie, X. et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for assessment of HER-2 status in breast cancer patients. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 29, 354–358 (2009). https://doi.org/10.1007/s11596-009-0318-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-009-0318-7

Key words

Search

Navigation